information.² The piano music began. The lifestyle montages followed. “Ask your doctor” entered the language like a civic duty.
Since then, pharmaceutical advertising has become one of the most reliable funding streams for American television. A Government Accountability Office report found manufacturers spent nearly $18 billion on direct-to-consumer advertising between 2016 and 2018—about $6 billion a year—with spending concentrated on a relatively small number of brand-name drugs.³
The country that pays the most for medicine is also the country most aggressively sold medicine.
That is not coincidence. It is architecture.
The phrase “ask your doctor” is not just polite branding. It is a behavioral lever. In a landmark study, standardized patients—actors trained to present scripted symptoms—visited real physicians. When those patients requested a specific antidepressant by name, prescribing rates rose significantly, even in clinically ambiguous scenarios.⁴ The request shifted the dynamic. Diagnosis became negotiation.
Advertising does not need to persuade millions. It needs to locate enough.
This is why the rare-disease campaigns are the most revealing. A biologic priced at $150,000 a year does not require ten million customers. It requires a few thousand insured ones. Capture 3,000 patients and you have $450 million in annual revenue. Manufacturing cost is often a fraction of that. Pricing reflects exclusivity, leverage, and what the system will bear.
It also reflects something more subtle: attention.
Many of the most powerful campaigns do not name a drug at all.
In 2016, viewers of General Hospital watched a beloved character receive a diagnosis of polycythemia vera—a rare blood cancer. The storyline was part of a disease-awareness partnership backed by Incyte, whose drug portfolio aligned with the condition’s molecular pathway.⁵ Oncologists publicly objected that a soap opera had become a clinical funnel.⁶
No brand name flashed across the screen. No price was mentioned.
But awareness spread.
During the Rio Olympics, Mylan ran heavy “unbranded” allergy awareness advertising at the height of the EpiPen pricing controversy.⁷ The campaign urged vigilance about severe allergic reactions. It did not need to say “EpiPen.” The rescue category was already clear.
More recently, Bristol Myers Squibb launched “Could It Be HCM?”—an unbranded awareness campaign fronted by NBA player Jared Butler, urging viewers to consider hypertrophic cardiomyopathy.⁸ Alexion produced film-style awareness projects around generalized myasthenia gravis, a rare autoimmune neuromuscular disease treated with high-cost biologics in its portfolio.⁹
These campaigns do not shout. They suggest. They invite. They lower the threshold at which normal human variance feels diagnostic.
Mass advertising for rare diseases is not about the masses. It is about finding the few.
Regulators have begun to respond.